Klothos Neurosciences Inc. (KLTO)

Overview

Klotho Neurosciences, Inc. is a pioneering biopharmaceutical company that focuses on the discovery and development of innovative therapeutic solutions for some of the most challenging diseases in the realm of oncology, cardiology, and neurology. With a specific emphasis on neurodegenerative disorders, the company leverages cutting-edge gene therapy techniques to address conditions that have limited treatment options. Originating as Anew Medical, Inc., the organization underwent a rebranding to Klotho Neurosciences, Inc. in September 2024, marking a new chapter in its commitment to advancing medical science. Rooted in Omaha, Nebraska, the company is strategically positioned to collaborate with a broad network of research institutions and clinical facilities, enhancing its research capabilities and accelerating the development of its therapeutic candidates.

Products and Services

The following are the lead gene therapy product candidates of Klotho Neurosciences, Inc.:

• AMI-101 for Alzheimer's Disease: This groundbreaking gene therapy candidate is designed for the treatment and potentially the prevention of Alzheimer’s disease. Alzheimer's disease is a progressive neurodegenerative disorder characterized by cognitive decline and a lack of effective treatments. AMI-101 targets the underlying genetic and molecular pathways implicated in the disease's progression, with the aim of slowing or halting its advancement.
• AMI-202 for Amyotrophic Lateral Sclerosis (ALS): AMI-202 is another promising gene therapy product in development aimed at treating and preventing amyotrophic lateral sclerosis, also known as Lou Gehrig’s disease. ALS is a fatal motor neuron disease that leads to muscle weakness, disability, and eventually, death. By targeting the specific genes associated with the disease, AMI-202 seeks to provide a significant breakthrough in ALS care, potentially improving life expectancy and quality of life for sufferers.